that you track the new information from KEYNOTE
426 and KEYNOTE 427, the OMNIVORE study,
JAVELIN Renal 101 and PROTECT, to name just a few.
For example, if you were looking for confirmatory evidence
underlying the rationale for using pembrolizumab
and axitinib in the frontline setting, then
review the findings from KEYNOTE 426.
Similarly, in the frontline setting, what are your
prognostic criteria when another combination,
avelumab and axitinib, is being considered? If we had a
MEDICAL INTELLIGENCE
(continued from page 36)
62 Kidney Cancer Journal
reliable biomarker with prognostic significance, treatment
choices could be further clarified. There has been
much interest in the neutrophil to lymphocyte ratio in
this regard and an abstract from this year’s meeting offers
data from a Phase 3 trial to potentially improve
clinical decision making.
Hopefully, by this time in 2021, we can gather again
at a “live” event to meet with our colleagues and reminisce
about a time when the vast halls of the convention
center were eerily empty and silent.
Robert A. Figlin, MD
Editor-in-Chief
EDITOR’S MEMO
(continued from inside front cover)
Ina® is compliant with the Health Insurance Portability and
Accountability Act (HIPAA). It brings a much-needed cancer
specific nutrition resource to the kidney cancer community.
A 2015 study in the Journal of Cachexia, Sarcopenia
and Muscle showed that 31.7% of metastatic renal cell carcinoma
(mRCC) patients were classified as being at risk of
malnutrition. Poor nutrition status and low body mass
index (BMI) scores were predictors of decreased survival
and poor quality of life among kidney cancer patients.
“The Kidney Cancer Association is delighted to share
this innovative new resource with the kidney cancer community,”
said Gretchen E. Vaughan, President and CEO of the
KCA. “Nutrition is a major concern for people living with
cancer and easy, quick, and relevant advice is crucial.
Especially now, when other aspects of life may feel outside
of their control, we hope that anyone impacted by kidney
cancer can feel empowered by the knowledge Ina provides.”
This partnership supports the KCA’s mission to provide
support and resources that empower people to make
informed decisions about their health. For more information
on how to use Ina®, please visit the KCA’s website at
https://www.kidneycancer.org/ina-by-savor-health. KCJ
28. Altoos B, Amini A, Yacoub M, et al. Local control rates of metastatic
renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions
using stereotactic body radiotherapy (SBRT).Radiat Oncol. 2015;
10:218.
29. Buti S, Bersanelli M, Viansone A, et al. Treatment outcome of
metastatic lesions from renal cell carcinoma undergoing extra-cranial
stereotactic body radiotherapy: the together retrospective study. Cancer
Treat Res Commun. 2020;22:10061.
30. Singh AK, Winslow TB, Kermany MH, et al. A pilot study of stereotactic
radiation therapy combined with cytoreductive nephrectomy for
metastatic renal cell carcinoma. Clin Can Res. 2017;23:5055-505.
31. Masini C, Iotti C, De Giorgi U, et al: Nivolumab in combination
with stereotactic body radiotherapy in pretreated patients with
metastatic renal cell carcinoma: First results of the phase II NIVES study.
2020 Genitourinary Cancers Symposium. Abstract 613. Presented February
15, 2020.
32. Hammers HJ, Vonmerveldt D, Ahn C, et al: Combination of dual
immune checkpoint inhibition with stereotactic radiation in metastatic
renal cell carcinoma. 2020 Genitourinary Cancers Symposium. Abstract
614. Presented February 15, 2020.
33. Chang et al. 2016 Clinical Oncology September 2016 Vol. 28, Issue
9, e109-e114 PMID 27131756
34. Staehler et al. 2015 PMID 25132240
35. Siva et al. 2017 BJUI 2017 PMID 28188682
36. Siva et al. 2018 Cancer PMID 29266183 KCJ
(continued from page 48)
/ina-by-savor-health